Nonalcoholic fatty liver disease (NAFLD) Affecting more than 30% of people worldwide, NAFLD is caused by the build-up of lipids within hepatic cells and has been linked to obesity, type 2 diabetes, and hyperlipidemia
Heres how they compare: Note: While both options may cause gastrointestinal discomfort, oral GLP-1 drugs tend to have fewer severe side effects, especially when it comes to injection-related issues
Is PT-141 supplied as a lyophilized powder
A 60-40 market share split, a $2 billion guidance raise, the only approved oral GLP-1, and a triple agonist pipeline candidate with nearly 29% weight loss in Phase 3 give Lilly structural advantages that compound over time
Ensure the needle you are using is long enough to fully penetrate the skin and reach the subcutaneous layer
Ryu J, Park SJ, Kim IH, Choi YH, Nam TJ